Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
266,941,931
-
Total 13F shares
-
111,597,128
-
Share change
-
+18,825,554
-
Total reported value
-
$1,515,160,970
-
Put/Call ratio
-
27%
-
Price per share
-
$13.58
-
Number of holders
-
184
-
Value change
-
+$263,628,807
-
Number of buys
-
122
-
Number of sells
-
55
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2020
As of 30 Jun 2020,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
184 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
111,597,128 shares.
The largest 10 holders included
BAUPOST GROUP LLC/MA, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Consonance Capital Management LP, Nantahala Capital Management, LLC, ABRAMS CAPITAL MANAGEMENT, L.P., STATE STREET CORP, GREAT POINT PARTNERS LLC, and D. E. Shaw & Co., Inc..
This page lists
184
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.